Community/research information only未获 FDA/EMA 批准WADA

Community protocol · IGF-1 LR3

IGF-1 LR3: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: Long R3 IGF-1 · IGF-1LR3

Sources checked: 27 August 2026

重要安全与责任声明

本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

IGF-1 LR3

常与生长、代谢及肌肉话题联系；作为未获批类似物，其安全性与获益尚未证实。

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amounts, timing and cycles

Community/research information only

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amount status

Different amounts circulate online; no regulator-confirmed safe or effective dose exists.

Profile evidence level: preclinical.

Timing

Community claims about time of day, fasting windows or training intervals are not validated clinical standards.

No individual recommendation.

Cycle/duration

Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

复配与 U-100 换算

复配计算器

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

复配计算器

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Total vial amount (mg)Fluid added (ml)Amount to calculate (µg)

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Long-acting experimental analogue of insulin-like growth factor 1

IGF-1 LR3 is classified as “Long-acting experimental analogue of insulin-like growth factor 1”. 常与生长、代谢及肌肉话题联系；作为未获批类似物，其安全性与获益尚未证实。 This describes the investigated pathway but does not validate a community use, amount, route or combination.

IGF-1剪接变体

这项研究考察生长因子IGF-1在组织中局部产生的变体如何参与肌肉细胞修复,类似于局部而非全身性的反应。在实验室模型中测量细胞生长和修复标志物。

生长轴放大

研究人员研究某物质如何放大从大脑到垂体再到生长激素的天然激素链,而不是直接补充生长激素。测量指标包括激素水平随时间的变化以及肌肉或脂肪量。

生长激素替代治疗

这项研究考察在确诊缺乏症的情况下直接给予重组生长激素,类似于补充身体本应产生却缺失的物质。临床研究中测量生长情况、身体成分和激素水平。

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

健身论坛

在这里,人们比较不同生长和修复肽之间的肌肉增长、力量提升和恢复时间,通常依据个人训练记录。商家和用户关于肌肉增长的说法属于个人经验之谈,而非对照研究结果。

来源与纯度讨论

人们讨论哪些商家被认为更值得信赖,以及不同批次之间纯度检测结果的差异。这类社区评估基于有限的样本,无法替代对每一批次进行的独立实验室检测。

兴奋剂与体育论坛

人们讨论在体育运动中使用提升表现的肽,包括参赛检测和监管禁用清单方面的经历。个人经验既不能证明疗效或安全性,也不能替代官方规则审查。

Adverse effects and risk boundaries

干预GH、IGF-1或其他激素轴可能引起水肿、关节或神经不适、糖耐量异常以及血压和激素变化；许多研究物质缺乏可靠人体数据。
Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

活动性或既往肿瘤、未控制糖尿病、颅内疾病、妊娠/哺乳及激素敏感性疾病均需专科评估；获批产品有具体禁忌。
Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

在有医学依据的使用中，IGF-1、空腹血糖/HbA1c、血压、体重/水肿、甲状腺及适应证相关激素可能需要评估；这不是自行检测方案。
Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

临床前

作为一种未获批准的类似物,其安全性和益处尚未得到证实。

Published evidence

现有数据主要来自动物或细胞模型;缺乏可靠的人体有效性和安全性数据。

IGF-1 LR3是内源性IGF-1经修饰后作用时间更长的类似物,而非生长激素本身。

Storage and stability

The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

未获 FDA/EMA 批准

没有 FDA 或 EMA 批准的药品；有效性与安全性尚未确立。

WADA 2026

This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.

WADA — 2026 Prohibited List

Comparisons and related profiles

Combinations / stacks

Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Sources and evidence layers

Primary sources and official registries take priority. The community reference is labelled separately.

Primary/technical sourcePubMed: MGF and IGF research
Primary/technical sourceWADA: 2026 prohibited list
Primary/technical sourceDailyMed — INCRELEX label (risk comparator; not LR3)
Community referenceIGF-1 LR3 — Peptide Dosing Protocols

Back to all 64 profiles Open scientific atlas profile